255.56

0.90% 2.28

After Hours: 255.00 -0.56 -0.22%

Johnson Johnson (JNJ)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Johnson Johnson stock is traded at $255.56, with a volume of 6.38M. It is up +0.90% in the last 24 hours and down -4.38% over the past month. Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Previous Close:

$253.28

Open:

$255.52

24h Volume:

6.38M

Relative Volume:

0.79

Market Cap:

$615.87B

Revenue:

$97.93B

Net Income/Loss:

$21.04B

P/E Ratio:

29.62

EPS:

8.6278

Net Cash Flow:

$17.80B

1W Performance:

-2.25%

1M Performance:

-4.38%

6M Performance:

+8.96%

1Y Performance:

+33.02%

1-Day Range:

$254.00

$257.55

1-Week Range:

$245.17

$264.39

52-Week Range:

$184.66

$281.07

Johnson Johnson Stock (JNJ) Company Profile

Name

Johnson Johnson

Sector

Healthcare (1052)

Industry

Drug Manufacturers - General (21)

Phone

732-524-2455

Address

ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ

Employee

140,800

Twitter

@jnjnews

Next Earnings Date

null

Latest SEC Filings

JNJ's Discussions on Twitter

Compare JNJ vs LLY, ABBV, MRK, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JNJ Johnson Johnson	255.56	615.87B	97.93B	21.04B	17.80B	8.6278
LLY Lilly Eli Co	1,257.03	1.12T	72.25B	25.28B	10.37B	27.78
ABBV Abbvie Inc	285.42	504.37B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	145.95	360.08B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	150.62	286.29B	54.66B	13.58B	16.05B	7.0171

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-02-26	Resumed	UBS	Buy
May-13-26	Upgrade	Leerink Partners	Market Perform → Outperform
Apr-08-26	Resumed	TD Cowen	Buy
Jan-28-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-13-25	Initiated	Scotiabank	Sector Outperform
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-10-24	Resumed	BofA Securities	Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral
May-30-24	Resumed	Goldman	Neutral
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-01-23	Upgrade	UBS	Neutral → Buy
Oct-05-23	Initiated	RBC Capital Mkts	Outperform
Sep-06-23	Initiated	HSBC Securities	Hold
May-30-23	Resumed	Citigroup	Buy
Mar-29-23	Initiated	UBS	Neutral
Mar-01-23	Initiated	Guggenheim	Neutral
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-14-22	Reiterated	BofA Securities	Neutral
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-17-21	Initiated	Goldman	Neutral
Dec-15-21	Reiterated	Citigroup	Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-28-21	Resumed	Morgan Stanley	Overweight
Apr-28-20	Downgrade	UBS	Buy → Neutral
Apr-22-20	Upgrade	BofA/Merrill	Neutral → Buy
Mar-05-20	Initiated	Citigroup	Buy
Dec-19-19	Upgrade	Barclays	Equal Weight → Overweight
Dec-17-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight
Oct-16-19	Upgrade	Atlantic Equities	Underweight → Neutral
Oct-11-19	Upgrade	Bernstein	Mkt Perform → Outperform
Jul-12-19	Resumed	Credit Suisse	Outperform
May-28-19	Initiated	Goldman	Buy
Jan-23-19	Reiterated	Barclays	Equal Weight
Jul-12-18	Upgrade	Goldman	Sell → Neutral
Jun-27-18	Initiated	Bernstein	Mkt Perform
Apr-23-18	Reiterated	Citigroup	Neutral
Apr-18-18	Reiterated	Stifel	Hold
Jan-24-18	Reiterated	Stifel	Hold
Jan-12-18	Reiterated	Wells Fargo	Outperform
Jan-02-18	Downgrade	JP Morgan	Overweight → Neutral
Oct-18-17	Reiterated	RBC Capital Mkts	Outperform
Oct-18-17	Reiterated	Stifel	Hold

View All

Johnson Johnson Stock (JNJ) Latest News

Oct 16, 2026

This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool

Oct 16, 2026

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research

Oct 15, 2026

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research

Oct 15, 2026

Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026

Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research

Oct 14, 2026

Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView

Oct 14, 2026

The Open Question Under Johnson & Johnson Stock’s Price - Trefis

Oct 14, 2026